Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women
Enrolling by invitation · Phase 2 · Has a placebo group
Conditions studied: Frail Elderly Syndrome
In brief
This is a pilot study to evaluate whether targeting inflammation will help reduce markers of insulin resistance inflammation, bone resorption and physical dysfunction in elderly women with gait disturbance. Positive results of this study would lead to the development of a larger clinical trial examining the effects of this intervention on age-related dysfunction.
Key facts
- Study ID
- NCT03430037
- Run by
- Mayo Clinic
- People needed
- 40
- Starts
- 2018-02-06
- Expected to finish
- 2027-11-01
- Last updated by the study team
- 2026-05-11
Who can join
Age: 70 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Healthy postmenopausal women
- Age ≥ 70 years
You may not qualify if…
- Abnormality in any of the screening laboratory studies (see below)
- Presence of significant liver or renal disease
- Malignancy (including myeloma)
- Malabsorption
- Hypoparathyroidism
- Hyperparathyroidism
- Acromegaly
- Cushing's syndrome
- Hypopituitarism
- Gastric bypass/reduction
- Malabsorption issues
- Crohn's
- Myopathies (increased or low calcium, vitamin D deficiency, elevated creatine kinase or ESR)
- If diabetic AND on sulfonylureas (like glipizide, glimepiride, glyburide), SGLT2 inhibitors (like dapagliflozin and empagliflozin), or insulin
- Undergoing treatment with any medications that affect bone turnover, including the following:
- adrenocorticosteroids (> 3 months at any time or > 10 days within the previous yr), anticonvulsant therapy (within the previous year),
- pharmacological doses of thyroid hormone (causing decline of thyroid stimulating hormone below normal),
- calcium supplementation of > 1200 mg/d (within the preceding 3 months),
- bisphosphonates (within the past 3 yrs),
- denosumab,
- estrogen (E) therapy or treatment with a selective E receptor modulator, or teriparatide (within the past yr).
- Subjects with a fracture within the past year
- Subjects taking potentially senolytic agents within the last year: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax
- Subjects currently taking drugs that induce cellular senescence: alkylating agents, anthracyclines, platins, other chemotherapy
- QTc >450 msec
Where it is running
- Mayo Clinic in Rochester — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.